your market intelligence analyst
Search Results
55 results
Your search is now limited to «Chemotherapy» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
Annals of Oncology 07/01/2019 20:00
Introduction: Current standard-of-care first-line treatments for metastatic pancreatic cancer (mPC) are associated with median progression-free survival (PFS) of approximately 6 months; the unmet need for effective and tolerable treatments in this setting is high.
Annals of Oncology 07/01/2019 20:00
Introduction: A fluoropyrimidine plus platinum compound has been used as the standard first-line chemotherapy for advanced gastric cancer (AGC). TAS-118 is an oral drug containing S-1 that is a fluoropyrimidine preparation combining tegafur, a prodrug of 5-fluorouracil, gimeracil, and oteracil potassium, and leucovorin. A randomized phase II study (S. Hironaka et al, Lancet Oncol. 2016) showed promising activity of S-1 plus leucovorin and oxaliplatin, compared with S-1 plus cisplatin in patients (pts) with AGC. We conducted a randomized, open-label, phase III trial (SOLAR study, NCT02322593) to evaluate the efficacy and safety of TAS-118 plus oxaliplatin vs. S-1 plus cisplatin in pts with AGC in Japan and Korea.
Annals of Oncology 07/01/2019 20:00
Introduction: The impact of sarcopenia as a predictor of poor prognosis and its association with chemotherapy toxicity have been explored in different cancer types but remain controversial in mGC. Our aim was to explore the correlation between sarcopenia, evaluated at baseline CT scan, and toxicity and efficacy of first-line therapy.
Annals of Oncology 07/01/2019 20:00
Introduction: Pancreatic cancer (PC) is one of the most aggressive and deadly malignancies. Gemcitabine (GEM) is the key agent in the first-line standard regimen for advanced PC, which is mostly diagnosed at advanced stage and unsuitable for curative resection. The objective response rate (ORR) and median progression-free survival (PFS) of various GEM-based regimens are still unsatisfactory. Therefore, development of new therapeutic modalities, including immunotherapy, is needed. This study aimed to investigate the efficacy, safety and clinical benefit of combination personalized immunotherapy with GEM and radiotherapy in locally advanced and metastatic PC patients.
Annals of Oncology 07/01/2019 20:00
Introduction: Long-term survival for advanced pancreatic ductal adenocarcinoma (PDAC) patients is poor. Active chemotherapy combinations are recommended in the first line (1L) setting for these patients. The decision to use Folfirinox or Nab-Paclitaxel plus Gemcitabine (NabPacGem) in 1L is a matter of debate as comparative trials have not been conducted so far.
Annals of Oncology 07/01/2019 20:00
Introduction: TAS-102 (Trifluridine and Tipiracil) is an oral cytotoxic agent used as a third-line treatment for metastatic colorectal cancer. The RECOURSE trial showed those treated with TAS-102 after progression on fluoropyrimidines had both progression-free survival and overall survival benefit compared to placebo, with response rates of 1.6%2. There are currently no validated biomarkers available to predict response to TAS-102, although work has suggested that neutropenia caused by TAS-102 in the first treatment cycle may be associated with better efficacy. We wished to review our real-world data from our centre’s experience with TAS-102 to review its efficacy, tolerance, and correlating factors that predict treatment benefit.
Annals of Oncology 07/01/2019 20:00
Introduction: Weekly paclitaxel is widely used in Japan as second-line chemotherapy in esophagogastric adenocarcinoma. There are no studies in the Mexican population. The aim of this study is to determine efficacy and toxicity of weekly paclitaxel for patients with advanced esophagogastric adenocarcinoma.
Annals of Oncology 07/01/2019 20:00
Introduction: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a promising laparoscopic intraperitoneal chemotherapy delivery technique, with improved drug distribution and deeper tissue penetration. Thus far, PIPAC oxaliplatin has been administered at an arbitrary dose of 92mg/m 2 . We aim to determine the dose-related safety profile and tolerability of PIPAC oxaliplatin.
Annals of Oncology 07/01/2019 20:00
Introduction: The optimal management of patients with locally advanced, unresectable, but nonmetastatic gastric cancer is uncertain, and there is no standard approach. FLOT, mDCF, and EOX are commonly used regimens in the neoadjuvant setting and may be used to render some patients resectable. Our objective is to compare the outcome of Taxane-based triplet with Anthracycline-based triplet as primary treatment for inoperable gastric adenocarcinoma.
Annals of Oncology 07/01/2019 20:00
Introduction: 5-fluorouracil (5-FU) is a key drug in the treatment of unresectable advanced gastric cancer (AGC). It is known that intravenous 5-FU and oral fluorouracil have different mechanisms as anti-cancer drugs, however, the clinical benefit of intravenous 5-FU after using oral fluorouracil is not clear. Therefore, we planned a prospective study to assess the efficacy and safety of weekly intravenous 5-FU and l-leucovorin(l-LV) in Japanese patients with AGC which was resistant to oral fluorouracil, taxane, and platinum.
Annals of Oncology 07/01/2019 20:00
... those results, as of July 2017, our center started to treat patients with clinical TNM staging of cT3 with mesorectal fascia invasion N0-N2, cT3N≥2 or cT4N0-N2, with neoadjuvant CRT followed by neoadjuvant chemotherapy (NAC) and then surgery.
Annals of Oncology 07/01/2019 20:00
Introduction: Capecitabine monotherapy for 6 months is a standard adjuvant treatment in stage II colorectal cancer without risk factors for relapse as well as in stage III patients over 70 years old. The starting dose of the drug in Europe is 1250mg/m2 bid, days 1-14, every 21 days. However due to side effects, often capecitabine dose is reduced and chemotherapy cycles are delayed or even omitted. With the current study, we aimed to examine the impact of reduced relative dose intensity (RDI) of the drug and the delivery of fewer cycles of chemotherapy on the recurrence rate in this group of patients.
Annals of Oncology 07/01/2019 20:00
Introduction: Palliative chemotherapy (CT) is the treatment of choice for advanced pancreatic adenocarcinoma and has been proven to improve survival in both the 1st and 2nd line setting, although prognosis remains poor. Treatment administration can be challenging and symptoms related to both cancer and CT often result in a deterioration of fitness and failure to tolerate treatment. According to registry data, survival outcomes at the Royal Marsden Hospital (RMH) appear to be highest in the UK despite having similar rates of surgical resection and acute presentation as other hepatobiliary centres. We sought to evaluate the use of palliative CT and outcomes for patients with advanced pancreatic adenocarcinoma at RMH.
Annals of Oncology 07/01/2019 20:00
Introduction: Anti-EGFR therapies are associated with the development of skin toxicities. These adverse events impact quality of life (QoL), increase patient risk for additional infections and lead to inconsistent anti-EGFR therapy administration. Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne and, at the same time, may avoid the development of antibiotic resistance related to the use of higher doses. However, the efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients treated with EGFR-targeted therapies has never been studied. The study objective was to assess the efficacy and safety of doxycycline in the prev.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications